Related Experiment Video
Updated: Jul 7, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
RAP250 is a coactivator in the transforming growth factor beta signaling pathway that interacts with Smad2 and Smad3
Per Antonson1, Tomas Jakobsson, Tova Almlöf
1Department of Biosciences and Nutrition, Karolinska Institutet, Novum, Huddinge, Sweden. per.antonson@biosci.ki.se
Abstract:
RAP250 is a coactivator for nuclear receptors as well as other transcription factors. Recent studies have established RAP250 as an essential coactivator for many important biological processes, but its exact mechanism of action is not fully understood. To identify novel proteins that can associate with RAP250, we used a yeast two-hybrid system to screen cDNA libraries and identified the intracellular mediators of transforming growth factor-beta (TGF-beta) response Smad2 and Smad3 as direct interacting proteins. We show that the interaction between RAP250 and Smad2/3 is dependent upon the second LXXLL interaction motif in RAP250 and the MH2 domain in Smad2 and Smad3. Mouse embryonic fibroblasts lacking RAP250 have reduced expression of the TGF-beta target gene PAI-1 after stimulation by TGF-beta when compared with wild type cells. Furthermore, we demonstrate a cross-talk between TGF-beta and liver X receptors (LXR) signaling pathways and show that stimulation of cells with TGF-beta and LXR agonists have a synergistic effect on the expression of the LXR target gene ABCG1. Our data identify RAP250 as a new coactivator in the TGF-beta signaling pathway that binds Smad2 and Smad3. Our data also suggest that the interaction between RAP250, Smad2, and Smad3 constitutes an important bridging mechanism linking LXR and TGF-beta signaling pathways.
Insights
RAP250 acts as a coactivator in transforming growth factor-beta (TGF-beta) signaling by binding Smad2 and Smad3. This interaction bridges TGF-beta and liver X receptors (LXR) pathways, impacting gene expression.
Area of Science:
- Molecular Biology
- Cell Signaling
- Gene Regulation
Background:
- RAP250 is a known coactivator for nuclear receptors and transcription factors.
- Its precise mechanism of action in biological processes requires further elucidation.
- Understanding RAP250's interactions is key to deciphering its role in cellular signaling.
Purpose of the Study:
- To identify novel protein partners of RAP250.
- To investigate the role of RAP250 in transforming growth factor-beta (TGF-beta) signaling.
- To explore potential cross-talk between TGF-beta and liver X receptor (LXR) signaling pathways mediated by RAP250.
Main Methods:
- Yeast two-hybrid screening to identify RAP250 interacting proteins.
- Co-immunoprecipitation assays to confirm protein interactions.
- Analysis of gene expression in mouse embryonic fibroblasts (MEFs) with and without RAP250.
- Stimulation assays using TGF-beta and LXR agonists.
Main Results:
- Smad2 and Smad3 were identified as direct binding partners of RAP250.
- The interaction involves specific motifs: the second LXXLL motif in RAP250 and the MH2 domain in Smad2/3.
- RAP250 deficiency in MEFs led to reduced TGF-beta target gene PAI-1 expression.
- A synergistic effect on LXR target gene ABCG1 expression was observed upon combined TGF-beta and LXR agonist stimulation.
Conclusions:
- RAP250 functions as a novel coactivator in the TGF-beta signaling pathway, directly interacting with Smad2 and Smad3.
- The RAP250-Smad2/3 complex serves as a crucial link between TGF-beta and LXR signaling pathways.
- This cross-talk mechanism influences the expression of key target genes in both pathways.
Related Concept Videos
TGF - β Signaling Pathway
Co-activators and Co-repressors
Co-activators and Co-repressors
MAPK Signaling Cascades
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Activation and Inactivation of G Proteins

